Longeveron Inc stock is traded at $1.81, with a volume of 1,786. It is down -0.55% in the last 24 hours and up +20.67% over the past month. Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Previous Close:
$1.82
Open:
$1.83
24h Volume:
1,786
Relative Volume:
0.01
Market Cap:
$6.11M
Revenue:
$1.22M
Net Income/Loss:
-$22.43M
P/E Ratio:
-
EPS:
-$1.16
Net Cash Flow:
-$18.78M
1W Performance:
-27.31%
1M Performance:
+20.67%
6M Performance:
-74.38%
1Y Performance:
-70.00%
1-Day Range:
$1.78$1.83
1-Week Range:
$1.78$2.53
52-Week Range:
$1.31$12.30
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron IncSector
HealthcareIndustry
BiotechnologyPhone
305-302-7158Address
1951 NW 7TH AVENUE, MIAMI, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS